← Back to patent-cliff list
CAS 1628567-06-5
(2R,3S,4R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-5-methoxytetrahydrofuran-3,4-diol
Codes: NAMOD-002
Application context (from source-drug indications)
Hepatocellular carcinomaNamodenosonLiver cirrhosisNamodenosonNon-alcoholic steatohepatitisNamodenosonPancreatic cancerNamodenosonChronic hepatitis CNamodenoson
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Namodenoson | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(2R,3S,4R)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3,4-diol→(2R,3S,4R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-5-methoxytetrahydrofuran-3,4-diol→(2R,3R,4R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-5-methoxytetrahydrofuran-3,4-diyl dibenzoate→(2R,3R,4R)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3,4-diyl dibenzoate→(2S,3S,4R)-3,4-bis(benzoyloxy)-5-methoxytetrahydrofuran-2-carboxylic acid→(3R,4S,5S)-2-methoxy-5-(methoxycarbonyl)tetrahydrofuran-3,4-diyl dibenzoate→(3R,4S,5S)-2-methoxy-5-(methylcarbamoyl)tetrahydrofuran-3,4-diyl dibenzoate→(3R,4S,5S)-2-acetoxy-5-(methylcarbamoyl)tetrahydrofuran-3,4-diyl dibenzoate→2-chloro-N-(3-iodobenzyl)-9H-purin-6-amine→(2R,3R,4S,5S)-2-(2-chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-5-(methylcarbamoyl)tetrahydrofuran-3,4-diyl dibenzoate→2,6-dichloro-9H-purine→(3-iodophenyl)methanamine hydrochloride→Namodenoson
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.